Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 4/20 | 0.47 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | TOP1 | P11387 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195861 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL1721047 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL2977597 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL1772055 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL5077543 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL124558 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL8371110 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL3027945 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL16027675 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT | |
| SCHEMBL8369765 | 1.00 | EP300 (0.64) | EP300GRIK1PPARGPPARATERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3842443-B1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2025-02-19 | — | — | EP | disclosed |
| EP-3842443-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | Cerenis Therapeutics Holding SA (FR) | 2021-06-30 | — | — | EP | disclosed |
| EP-3363805-B1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20190008757-A1 | DERMATOLOGICAL OR COSMETIC COMPOSITIONS CONTAINING A POLYPHENOL?ENRICHED EXTRACT OF VITEX NEGUNDO | LABORATOIRES EXPANSCIENCE (FR) | 2019-01-10 | — | — | US | disclosed |
| EP-3363805-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | Cerenis Therapeutics Holding SA (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-20170204122-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-07-20 | — | — | US | disclosed |
| US-9708354-B2 | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-07-18 | — | — | US | disclosed |
| US-9643915-B2 | Methods for the synthesis of sphingomyelins and dihydrosphingomyelins | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-05-09 | — | — | US | disclosed |
| US-20160075634-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-03-17 | — | — | US | disclosed |
| EP-2970344-A2 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | Cerenis Therapeutics Holding SA (FR) | 2016-01-20 | — | — | EP | disclosed |
| US-20140316154-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2014-10-23 | — | — | US | disclosed |
| WO-2014140787-A2 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275590-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2014-09-18 | — | — | US | disclosed |
| US-5012000-A | Total synthesis of chiral 2-amino-1,3-diols | EASTMAN KODAK COMPANY (US) | 1991-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190008757-A1 | DERMATOLOGICAL OR COSMETIC COMPOSITIONS CONTAINING A POLYPHENOL?ENRICHED EXTRACT OF VITEX NEGUNDO | CUTA, TYR, KRT18 | EP300 277/4885GRIK1 4196/4885PPARG 151/4885 |
| US-20140316154-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | SGMS1, SGMS2, CERS2 | EP300 3953/4885GRIK1 3414/4885PPARG 4736/4885 |
| US-20160075634-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | SGMS1, SGMS2, CERS2 | EP300 3953/4885GRIK1 3414/4885PPARG 4736/4885 |
| US-20140275590-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | SGMS1, SGMS2, CERS2 | EP300 3953/4885GRIK1 3414/4885PPARG 4736/4885 |
| US-20170204122-A1 | METHODS FOR THE SYNTHESIS OF SPHINGOMYELINS AND DIHYDROSPHINGOMYELINS | SGMS1, SGMS2, CERS2 | EP300 3953/4885GRIK1 3414/4885PPARG 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.